Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.69
ACUR's Cash to Debt is ranked lower than
63% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. ACUR: 0.69 )
Ranked among companies with meaningful Cash to Debt only.
ACUR' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.61 Max: No Debt
Current: 0.69
Equity to Asset -0.06
ACUR's Equity to Asset is ranked lower than
97% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ACUR: -0.06 )
Ranked among companies with meaningful Equity to Asset only.
ACUR' s Equity to Asset Range Over the Past 10 Years
Min: -7.86  Med: -0.61 Max: 0.97
Current: -0.06
-7.86
0.97
F-Score: 2
Z-Score: -70.48
M-Score: -3.01
WACC vs ROIC
16.97%
-525.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -266.31
ACUR's Operating margin (%) is ranked lower than
91% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.25 vs. ACUR: -266.31 )
Ranked among companies with meaningful Operating margin (%) only.
ACUR' s Operating margin (%) Range Over the Past 10 Years
Min: -11455.28  Med: -214.32 Max: 51.47
Current: -266.31
-11455.28
51.47
Net-margin (%) -291.24
ACUR's Net-margin (%) is ranked lower than
91% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. ACUR: -291.24 )
Ranked among companies with meaningful Net-margin (%) only.
ACUR' s Net-margin (%) Range Over the Past 10 Years
Min: -11301.63  Med: -225.57 Max: 50.74
Current: -291.24
-11301.63
50.74
ROE (%) -218.36
ACUR's ROE (%) is ranked lower than
98% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. ACUR: -218.36 )
Ranked among companies with meaningful ROE (%) only.
ACUR' s ROE (%) Range Over the Past 10 Years
Min: -218.36  Med: -47.07 Max: 51.89
Current: -218.36
-218.36
51.89
ROA (%) -72.04
ACUR's ROA (%) is ranked lower than
93% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ACUR: -72.04 )
Ranked among companies with meaningful ROA (%) only.
ACUR' s ROA (%) Range Over the Past 10 Years
Min: -349.87  Med: -36.27 Max: 33.14
Current: -72.04
-349.87
33.14
ROC (Joel Greenblatt) (%) -875.17
ACUR's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. ACUR: -875.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACUR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1226.13  Med: -945.65 Max: 1628.06
Current: -875.17
-1226.13
1628.06
EBITDA Growth (3Y)(%) -31.40
ACUR's EBITDA Growth (3Y)(%) is ranked lower than
91% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. ACUR: -31.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACUR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.2  Med: -13.4 Max: 50.5
Current: -31.4
-60.2
50.5
EPS Growth (3Y)(%) -22.80
ACUR's EPS Growth (3Y)(%) is ranked lower than
83% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. ACUR: -22.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACUR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -84.9  Med: -8.8 Max: 56.4
Current: -22.8
-84.9
56.4
» ACUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ACUR Guru Trades in Q4 2015

Jim Simons 52,820 sh (+8.19%)
» More
Q1 2016

ACUR Guru Trades in Q1 2016

Jim Simons 58,120 sh (+10.03%)
» More
Q2 2016

ACUR Guru Trades in Q2 2016

Jim Simons 75,620 sh (+30.11%)
» More
Q3 2016

ACUR Guru Trades in Q3 2016

Jim Simons 81,920 sh (+8.33%)
» More
» Details

Insider Trades

Latest Guru Trades with ACUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:APRI, OTCPK:RLMD, NAS:BNTC, OTCPK:AQSZF, OTCPK:PVCT, AMEX:IGC, NAS:MYOS, OTCPK:IMLFF, OTCPK:NRXCF, NAS:PARN, OTCPK:CYIG, OTCPK:RSPI, NAS:DCTH, OTCPK:ULUR, OTCPK:CVSI, OTCPK:PUFXF, NAS:OCLS, OTCPK:PTLF, OTCPK:ADMD, OTCPK:TRLPF » details
Traded in other countries:HD4B.Germany,
Acura Pharmaceuticals Inc is a pharmaceutical company. It is engaged in the research, development & manufacture of product to address medication abuse & misuse, utilizing the Company's proprietary, tamper-resistant AVERSION & IMPEDE technology platforms.

Acura Pharmaceuticals Inc is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Technologies. The Company has discovered and developed two proprietary technologies; Aversion Technology and Impede Technology. Its Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Pfizer Inc.s Oxecta or oxycodone HCl tablets CII is the first approved and marketed product utilizing Aversion and is commercialized under its license agreement with a subsidiary of Pfizer, or the Pfizer Agreement. The Company has also developed its Impede Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. It has 7 additional opioid products utilizing Aversion in various stages of development. It also launched Nexafed commercially in mid-December 2012. The Pfizer Agreement grants Pfizer an exclusive license to develop and commercialize Oxecta. Its potential competitors include, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet Corporation, KemPharm, Shionogi, Nektar Therapeutics, Signature Therapeutics, QRx Pharma, Tris Pharma, Pisgah Labs, and Collegium Pharmaceuticals, Inc. The Company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act and to a lesser extent, by state and local governments.

Ratios

vs
industry
vs
history
P/S 3.17
ACUR's P/S is ranked lower than
51% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. ACUR: 3.17 )
Ranked among companies with meaningful P/S only.
ACUR' s P/S Range Over the Past 10 Years
Min: 2.19  Med: 10.33 Max: 1011.11
Current: 3.17
2.19
1011.11
Current Ratio 1.26
ACUR's Current Ratio is ranked lower than
78% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ACUR: 1.26 )
Ranked among companies with meaningful Current Ratio only.
ACUR' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.58 Max: 68.17
Current: 1.26
0.02
68.17
Quick Ratio 1.16
ACUR's Quick Ratio is ranked lower than
69% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. ACUR: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
ACUR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 1.36 Max: 68.17
Current: 1.16
0.01
68.17
Days Inventory 205.68
ACUR's Days Inventory is ranked lower than
83% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.28 vs. ACUR: 205.68 )
Ranked among companies with meaningful Days Inventory only.
ACUR' s Days Inventory Range Over the Past 10 Years
Min: 161.36  Med: 446.2 Max: 752.41
Current: 205.68
161.36
752.41
Days Sales Outstanding 18.26
ACUR's Days Sales Outstanding is ranked higher than
92% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.78 vs. ACUR: 18.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.73  Med: 31.49 Max: 575.69
Current: 18.26
2.73
575.69
Days Payable 357.90
ACUR's Days Payable is ranked higher than
96% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.88 vs. ACUR: 357.90 )
Ranked among companies with meaningful Days Payable only.
ACUR' s Days Payable Range Over the Past 10 Years
Min: 61.2  Med: 348.92 Max: 877.28
Current: 357.9
61.2
877.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.80
ACUR's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. ACUR: -8.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACUR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -166.7  Med: -8.8 Max: -0.9
Current: -8.8
-166.7
-0.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.32
ACUR's Price/Median PS Value is ranked higher than
96% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. ACUR: 0.32 )
Ranked among companies with meaningful Price/Median PS Value only.
ACUR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.51 Max: 105.56
Current: 0.32
0.05
105.56
Earnings Yield (Greenblatt) (%) -65.77
ACUR's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ACUR: -65.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACUR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -72.74  Med: 8.7 Max: 48.2
Current: -65.77
-72.74
48.2

More Statistics

Revenue (TTM) (Mil) $3.38
EPS (TTM) $ -0.82
Beta2.34
Short Percentage of Float0.63%
52-Week Range $0.85 - 3.52
Shares Outstanding (Mil)11.83

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 32 87
EPS ($) -0.89 -0.48 0.45 1.11
EPS w/o NRI ($) -0.89 -0.48 0.45 1.11
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ACUR

Headlines

Articles On GuruFocus.com
What to Watch for: November 3-7 Nov 04 2014 
Acura Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 02 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 29 2010 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 26 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 30 2009 
Acura Pharmaceuticals Inc. Reports Operating Results (10-Q) May 01 2009 

More From Other Websites
ETFs with exposure to Acura Pharmaceuticals, Inc. : December 7, 2016 Dec 07 2016
ACURA PHARMACEUTICALS, INC Financials Nov 22 2016
Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 15 2016
ACURA PHARMACEUTICALS, INC Files SEC form 10-Q, Quarterly Report Nov 14 2016
Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results Nov 14 2016
Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results Nov 14 2016
Q3 2016 Acura Pharmaceuticals Inc Earnings Release - After Market Close Nov 14 2016
Acura Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call on November 15,... Nov 09 2016
Acura Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call on November 15,... Nov 09 2016
ETF’s with exposure to Acura Pharmaceuticals, Inc. : October 18, 2016 Oct 18 2016
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent... Oct 18 2016
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion(R) Abuse-Deterrent... Oct 18 2016
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Oct 18 2016
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion(R) Abuse-Deterrent... Oct 18 2016
KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent... Oct 18 2016
ETF’s with exposure to Acura Pharmaceuticals, Inc. : October 7, 2016 Oct 07 2016
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Oct 06 2016
ETF’s with exposure to Acura Pharmaceuticals, Inc. : August 18, 2016 Aug 18 2016
ACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Aug 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)